Henlius Denosumab Biosimilar Trial Enters Phase III
As Firm’s Shanghai Plant Has Received EU GMP Equivalence
Executive Summary
Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.
You may also be interested in...
Sandoz Follows US Denosumab Filing With European Acceptance
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
Sandoz Maintains Lead On Denosumab As It Files With FDA
Sandoz has confirmed that its denosumab biosimilar BLA has been accepted for review by the US FDA. The company – which has previously characterized its development program as a frontrunner compared to other proposed Prolia/Xgeva rivals – indicated that it was “among the first” to file.
Luye Claims A First With Chinese Denosumab Approval
Luye Pharma has claimed a world first after its Boan Biotech subsidiary obtained an approval from China’s NMPA for its Boyoubei denosumab biosimilar rival to Amgen’s Prolia.